Literature DB >> 15084839

Differential expression of WT1 and p53 in serous and endometrioid carcinomas of the endometrium.

Jennifer A Egan1, Marina C Ionescu, Elizabeth Eapen, Joan G Jones, David S Marshall.   

Abstract

Wilms' tumor antibody (WT1) has recently been reported to be reactive in most ovarian and peritoneal serous carcinomas, but few studies have looked at WT1 reactivity in endometrial carcinomas. p53, like WT1, is a tumor suppressor gene and in its mutated form is frequently present in endometrial serous carcinoma. Routine immunohistochemical staining for p53 and WT1 was performed in 70 endometrial carcinomas (39 endometrioid and 31 serous) of varying differentiation using tissue microarrays. Only 2 (7.5%) serous carcinomas and none of the endometrioid carcinomas (0%) were reactive for WT1. p53 immunoreactivity was found in 26 (83.9%) serous carcinomas and in 2 (5.1%) endometrioid carcinomas. We conclude that WT1 and p53 expression are not related and that WT1 expression in endometrial serous carcinoma differs from that of its extrauterine counterparts.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15084839     DOI: 10.1097/00004347-200404000-00005

Source DB:  PubMed          Journal:  Int J Gynecol Pathol        ISSN: 0277-1691            Impact factor:   2.762


  5 in total

Review 1.  Development of targeted therapy in uterine serous carcinoma, a biologically aggressive variant of endometrial cancer.

Authors:  Karim S El-Sahwi; Peter E Schwartz; Alessandro D Santin
Journal:  Expert Rev Anticancer Ther       Date:  2012-01       Impact factor: 4.512

2.  Carcinomas of Distal Fallopian Tube and Their Association with Tubal Intraepithelial Carcinoma: Do They Share a Common "Precursor" Lesion? Loss of Heterozygosity and Immunohistochemical Analysis Using PAX 2, WT-1, and P53 Markers.

Authors:  Mamatha Chivukula; Leo A Niemeier; Robert Edwards; Marina Nikiforova; Geetha Mantha; Kim McManus; Gloria Carter
Journal:  ISRN Obstet Gynecol       Date:  2010-12-15

3.  Evaluation of the incidence and clinical significance of WT-1 expression in uterine serous carcinoma.

Authors:  Jennifer McEachron; Agha Wajdan Baqir; Nancy Zhou; Absia Jabbar; Raavi Gupta; Daniel Levitan; Yi-Chun Lee
Journal:  Gynecol Oncol Rep       Date:  2021-12-27

Review 4.  An Algorithmic Immunohistochemical Approach to Define Tumor Type and Assign Site of Origin.

Authors:  Andrew M Bellizzi
Journal:  Adv Anat Pathol       Date:  2020-05       Impact factor: 4.571

5.  ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up.

Authors:  Nicoletta Colombo; Carien Creutzberg; Frederic Amant; Tjalling Bosse; Antonio González-Martín; Jonathan Ledermann; Christian Marth; Remi Nout; Denis Querleu; Mansoor Raza Mirza; Cristiana Sessa
Journal:  Int J Gynecol Cancer       Date:  2016-01       Impact factor: 3.437

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.